Kennedy Lets Pharmacies Compound Six Unapproved Peptides as FDA Scientists Warn of Risks

WASHINGTON — The Department of Health and Human Services has opened a regulated path for six unapproved peptide drugs that have become fixtures of the wellness market, announcing on Wednesday, 28 October 2026, that the Food and Drug Administration will not take enforcement action against licensed pharmacies and physicians that compound them under specified conditions. The interim policy, published in the Federal Register as an exercise of enforcement discretion by Health Secretary Robert F. Kennedy Jr., is a governing decision, not a campaign one: it changes what a federal regulator will, in practice, allow to be made and sold.

The six substances are BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. None has passed the FDA’s review for safety and effectiveness, and compounded medicines are not FDA-approved products, which means the agency does not assess their safety, effectiveness or quality before they reach patients. That distinction is the heart of the dispute that followed within hours. Supporters describe the policy as a pragmatic attempt to pull an already large trade out of an unregulated online grey market and into pharmacies that must meet testing and reporting conditions. Critics, including the FDA’s own career scientists according to reporting on the process, describe it as the department setting aside its own drug reviewers and exposing patients to products whose benefits and harms have not been established as American drug law normally requires.

Both descriptions can be true at once. Demand is real and is already being met by overseas sellers of products labelled for research use only. The evidence base is also, by the FDA staff’s earlier assessment, thin enough that the agency previously advised pharmacies not to compound at least two of them. The policy is therefore a judgement about which risk the government prefers: an unregulated market it cannot see, or a regulated one it has not fully endorsed. This article sets out both cases.

What the Interim Policy Actually Does

Enforcement discretion is a limited tool, and its limits matter. The department has not declared the six peptides safe, effective or approved, and has not added them permanently to the list of bulk substances permitted in compounding. Instead, while a formal decision is pending, the FDA will not pursue state-licensed pharmacies, federal facilities or licensed physicians that compound them if they meet the policy’s conditions. The interim arrangement is intended to remain until the FDA develops, through ordinary rulemaking, its 503A Bulks List of permitted substances. Rulemaking can take months or longer, so an interim policy can shape the market for a substantial period.

The conditions are the policy’s answer to the safety objection. A compounder must source the ingredient from a facility registered with the FDA and hold a valid certificate of analysis whose test results meet the criteria in FDA guidance. Compounders must report serious adverse events and product quality problems to the agency. Requirements also apply to manufacturing standards, labelling and patient-specific prescriptions, meaning products are made for an identified patient under prescription rather than as ordinary retail stock. The department has also said it may reconsider the policy if safety signals or quality problems emerge.

The policy’s reach is also narrower than headlines may suggest. NPR reporting explains that it creates a path for smaller 503A compounding pharmacies, which prepare medicines for individual patients, and does not extend in the same way to larger 503B outsourcing facilities that produce in higher volumes. That limitation keeps the opening focused on patient-specific compounding, but also constrains supply, because smaller facilities were never built for a mass wellness market.

The Six Peptides and Why People Want Them

Peptides are short chains of amino acids, the building blocks of protein. Some occur naturally, others are synthetic, and the category is not exotic: several approved medicines for diabetes and weight management are peptides that completed the full FDA process. The six substances here are promoted for uses that remain proposed rather than proven, and those uses should be read as claims by sellers, clinicians and advocates, not as established treatments.

According to the reporting reviewed for this story, BPC-157 has been proposed for ulcerative colitis and is widely used for injury recovery; TB-500 is proposed for wound healing, and the two are often taken together in a combination enthusiasts call the Wolverine stack. Epitalon is proposed for insomnia, KPV for wound healing and inflammatory conditions, MOTS-c for obesity, osteoporosis and metabolic health, and Semax for migraines, chronic pain and conditions involving reduced blood flow to the brain. Influencers and some clinicians have promoted products across this range for anti-ageing, recovery, energy and memory, and use has grown sharply over the past year even though compounding them was not permitted until this week.

Secretary Kennedy’s own position is part of the story. He has described himself as a big fan of peptides, vowed to make them more available, and said he used BPC-157 himself for a muscle injury, according to Associated Press reporting. A personal endorsement by a health secretary is not evidence about a drug. It is, however, relevant context for why this department acted through the secretary’s office rather than waiting for the FDA’s normal process, and why critics have focused on the process as much as on the substances.

A July Vote, and a Split Inside the Government

The immediate foundation is a vote in July by the FDA’s Pharmacy Compounding Advisory Committee, which recommended over a two-day meeting that all six peptides be allowed in compounding and added to the 503A list. The department points to that recommendation as the basis for concluding that limited compounding under safeguards advances patient choice while protecting safety. On the surface, that is the ordinary machinery of regulation: an advisory committee weighs a question, and the agency acts on its advice.

The complication, reported consistently across several outlets, is that the FDA’s own staff recommended against the same step, arguing the evidence did not justify easing restrictions. Associated Press reporting, based on six people familiar with the process, says FDA drug staff had limited input into the policy and largely opposed it. There were also questions about the committee itself. Before the July meeting, the agency appointed eight new members, several of whom were reported to have ties to businesses or clinics that prescribe or promote peptides. The department has said all members passed standard ethics checks. Those two facts should be kept together; neither, on its own, establishes that any member acted improperly.

In 2023, the FDA placed BPC-157, TB-500 and more than a dozen other peptides on a list of substances it said pharmacies should not compound, citing risks including allergic reactions, kidney damage and tumour growth. Compounding oversight has been sensitive since a 2012 fungal meningitis outbreak traced to contaminated injections from a Massachusetts pharmacy, after which scrutiny tightened. That history does not prove any one of the six substances will cause harm. It does explain why agency scientists have treated popularity, on its own, as an insufficient reason to reverse a safety position set out in writing three years earlier.

What Supporters Say Patients Gain

The administration’s core argument is about the alternative that already exists. Patients are already obtaining these substances in large numbers as research-use-only products from foreign manufacturers, bought online with no pharmacy standards, no verified purity testing a patient can inspect, and no obligation on anyone to report a bad reaction to the FDA. A limited compounding policy under safeguards, the department argues, gives those patients a more controlled route, from a licensed pharmacy that can be inspected and acted against. There is, the policy notes, significant interest in these peptides precisely because no approved products exist for patients seeking them.

Parts of the pharmacy world have welcomed the decision in similar terms. Lee Rosebush, who chairs the American Academy of Peptide Medicine, described it to Reuters as a landmark regulatory milestone clearing a path for innovation and wider access. Scott Brunner, chief executive of the Alliance for Pharmacy Compounding, said the decision offers patients a more accountable alternative, bringing them into a system where pharmacy standards, oversight and adverse event reporting apply. Those are industry voices with an interest in the outcome, but the point they make — that a reported side effect is easier to detect than an unreported one — is a genuine feature of the policy’s design.

Even supportive pharmacists warn patients not to expect immediate availability. Joshua Fritzler, president of Olympia and Wesley Pharmaceuticals in central Florida, told NPR that people have asked about these peptides for years, but only his firm’s smaller operation can produce them now, in small quantities, and it will likely compound just one of the six at first. Suppliers must also confirm their ingredients meet the policy’s requirements, a process the Alliance for Pharmacy Compounding has said will take time. Analysts cited in reporting estimate the peptide market could reach between 2 billion and 3 billion dollars if legitimised, and telehealth companies including Hims & Hers Health have been preparing offerings in anticipation of clearance. Those figures are estimates about a possible future market, not measurements of current sales.

What Critics Say Is at Stake

The opposition is led by consumer and patient-safety groups, and its argument is about both risk and precedent. Robert Steinbrook, director of Public Citizen’s Health Research Group, urged the department to rescind the policy, saying the secretary had acted recklessly and unilaterally and undermined the FDA by allowing unproven and potentially unsafe peptides to be made, marketed and prescribed without normal federal enforcement. In Public Citizen’s account, every peptide should go through the standard FDA approval process, in which a sponsor must generate evidence of safety and effectiveness before a product is sold. Steinbrook has also pointed to the specific risks patients should be told about, including contamination, impurities and side effects that cannot yet be characterised because the products have not been studied as approved drugs are.

Researchers at the Center for Science in the Public Interest, writing in a JAMA Viewpoint article discussed by the Regulatory Affairs Professionals Society, made the precedent argument in its sharpest form. If the size of a grey market becomes a reason to permit a substance, they argued, the same logic could be applied to any compound whose unlawful sales grew large enough. They also warned that free compounding removes much of the incentive for any company to run the expensive clinical trials that would establish whether a substance works, because a firm that paid for that evidence would compete against sellers who never had to. Peter Lurie, the centre’s director and a former FDA official, has separately argued that the FDA lacks the legal power to enforce all of the plan’s safeguards, and that patients may be diverted from well-tested, approved medicines for conditions such as insomnia and migraine.

Other critics have focused on what the policy leaves unresolved. The Partnership for Safe Medicines, whose members include pharmacy organisations, filed a citizen petition last week asking the FDA to disregard the July recommendation, and its executive director, Shabbir Safdar, said the decision leaves Americans in a grey area about whether the peptides are safe. Jeff Cohen, a co-founder of the American Peptide Association, raised a practical point reported by Reuters: state regulators may not follow the federal lead. Compounding is overseen jointly by the FDA and state pharmacy boards, so a federal decision not to enforce does not guarantee every state will permit the same activity. Patients may face a patchwork in which a product is tolerated federally and still restricted where they live.

What Happens Next

The next formal step belongs to the FDA’s rulemaking process, in which the agency must decide, substance by substance, whether these peptides belong on the permanent 503A list. HealthDay reporting on the Associated Press and Washington Post coverage notes that the public was to have two weeks to comment before the policy is finalised, an unusually short window for an interim measure. Until the permanent list is settled, the enforcement policy is the operative document, and the department’s stated condition — that it may reconsider if safety signals emerge — means the adverse event reports filed in the coming months carry unusual weight. A clean early record will strengthen the administration’s case; a cluster of serious reports would give the FDA staff who opposed the policy documented grounds to revisit it.

For patients, the advice in the reporting from every side is consistent. These substances are not approved drugs, and their proposed uses are claims, not findings. Anyone considering them should discuss contamination risk, unknown side effects and approved alternatives with the prescribing clinician, and use a licensed pharmacy operating under the policy’s conditions rather than an overseas website. Secretary Kennedy has staked part of his tenure on widening access to treatments the regulatory system has kept at arm’s length. Whether this move is remembered as bringing a risky grey market under supervision, or as setting the approval standard aside, will depend on evidence not yet collected — which is exactly what the two sides are arguing about.

Sources

USN reviewed reporting from multiple outlets for this story. Read more from Reuters, NPR and RAPS.